OncoSec to Present at Investment Conferences in October

SAN DIEGO, Oct. 5, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present at two high-profile investment conferences in October: Aegis Capital Corp. 2015 Growth Conference and 14th Annual BIO Investor Forum.

Aegis Capital Corp. 2015 Growth Conference

Mr. Dhillon will present a corporate overview at the Aegis Capital Corp. 2015 Growth Conference on October 8 at 4:00 PM PT located in Brahms 2 at The Encore at Wynn Las Vegas. To join the live webcast, please access the following link at the time of the presentation: http://wsw.com/webcast/aegis2/oncs. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.

The conference is expected to bring more than 100 presenting companies and more than 500 individuals together for three days of one-on-one meetings and various networking events. The conference serves as a platform for individuals in the healthcare, technology, telecom, and aerospace-defense sectors to network and discuss innovations in their respective fields. For more information, please visit: http://www.aegiscapcorp.com/.

14th Annual BIO Investor Forum

Mr. Dhillon will present a corporate overview at the 14th Annual BIO Investor Forum on October 21 at 9:30 AM PT at Parc 55 San Francisco.

The forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and one-on-one meetings. For more information, please visit: https://www.bio.org/events/conferences/14th-annual-bio-investor-forum. 

About OncoSec Medical Incorporated

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer.  ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.

Contact
Investor Relations:
Jordyn Kopin
OncoSec Medical Incorporated
855-662-6732
[email protected] 

Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
[email protected]

Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

SOURCE OncoSec Medical Incorporated

Related Links

http://www.oncosec.com